MIRM
Mirum Pharmaceuticals, Inc. NASDAQ Listed Jul 18, 2019$102.89
Mkt Cap $5.2B
52w Low $40.00
87.3% of range
52w High $112.00
50d MA $93.89
200d MA $80.49
P/E (TTM)
-205.4x
EV/EBITDA
231.8x
P/B
15.4x
Debt/Equity
1.0x
ROE
-7.4%
P/FCF
72.3x
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
$93.89
200d MA
$80.49
Avg Volume
812.9K
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
950 Tower Lane · Foster City, CA 94404 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.39 | -13.43 | -3308.6% | 110.08 | +0.0% | -6.5% | +4.1% | — | — | — | — |
| Feb 25, 2026 | AMC | 0.02 | -0.11 | -650.0% | 108.62 | -11.1% | -15.1% | +0.1% | -2.4% | -2.5% | +6.0% | — |
| Nov 4, 2025 | AMC | -0.10 | 0.05 | +150.0% | 70.97 | +3.5% | -1.2% | -3.4% | +0.6% | +2.3% | +2.3% | — |
| Aug 6, 2025 | AMC | -0.31 | -0.12 | +61.3% | 53.39 | +3.5% | +12.0% | +0.3% | +9.8% | -1.7% | +0.6% | — |
| May 7, 2025 | AMC | -0.39 | -0.30 | +23.1% | 41.22 | -3.0% | +9.8% | -2.1% | +2.9% | -0.7% | -1.9% | — |
| Feb 26, 2025 | AMC | -0.27 | -0.49 | -81.5% | 50.52 | -3.0% | -7.0% | +1.3% | -3.3% | -1.7% | -1.3% | — |
| Nov 12, 2024 | AMC | -0.45 | -0.30 | +33.3% | 42.28 | +2.1% | +3.9% | +5.3% | -3.8% | -6.9% | +1.6% | — |
| Aug 7, 2024 | AMC | -0.48 | -0.52 | -8.3% | 38.96 | +0.0% | +2.3% | +0.4% | +11.8% | -8.2% | +1.0% | — |
| May 8, 2024 | AMC | -0.40 | -0.54 | -35.0% | 25.04 | +2.6% | +3.2% | -4.1% | +0.1% | +0.1% | +0.8% | — |
| Feb 28, 2024 | AMC | -0.34 | -0.66 | -94.1% | 28.89 | -1.0% | -0.6% | +2.0% | -2.0% | -2.4% | +1.5% | — |
| Nov 2, 2023 | AMC | -0.64 | -0.57 | +10.9% | 28.39 | +5.3% | +5.7% | -2.2% | +2.2% | -0.9% | -4.2% | — |
| Aug 3, 2023 | AMC | -0.81 | -0.92 | -13.6% | 24.88 | -0.7% | +6.3% | -2.9% | -0.9% | +1.3% | +1.9% | — |
| May 4, 2023 | AMC | -0.96 | -0.80 | +16.7% | 27.85 | +2.8% | -5.8% | +0.5% | -0.2% | -0.5% | +0.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Stifel | Maintains | Buy → Buy | — | $94.00 | $93.85 | -0.2% | +0.2% | +3.3% | -0.8% | +9.6% | +0.0% |
| Apr 28 | Baird | Maintains | Outperform → Outperform | — | $92.48 | $93.34 | +0.9% | +1.6% | +0.2% | +3.3% | -0.8% | +9.6% |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $91.49 | $92.00 | +0.6% | +1.1% | +1.6% | +0.2% | +3.3% | -0.8% |
| Apr 21 | Citizens | Maintains | Market Outperform → Market Outperform | — | $95.71 | $95.08 | -0.7% | -2.5% | +1.1% | -2.5% | -0.5% | +1.1% |
| Mar 27 | TD Cowen | Maintains | Buy → Buy | — | $88.88 | $89.42 | +0.6% | -0.5% | -0.6% | +5.1% | +2.4% | -0.5% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.51 | $88.77 | +0.3% | +1.0% | -1.7% | +2.6% | -1.4% | -0.5% |
| Mar 4 | Evercore ISI | Maintains | Outperform → Outperform | — | $87.80 | $89.16 | +1.5% | +6.0% | -5.6% | -1.8% | +2.9% | +2.4% |
| Feb 26 | Leerink Partners | Maintains | Outperform → Outperform | — | $108.62 | $96.53 | -11.1% | -15.1% | +0.1% | -2.4% | -2.5% | +6.0% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $108.62 | $96.53 | -11.1% | -15.1% | +0.1% | -2.4% | -2.5% | +6.0% |
| Feb 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $108.62 | $96.53 | -11.1% | -15.1% | +0.1% | -2.4% | -2.5% | +6.0% |
| Feb 26 | Stifel | Maintains | Buy → Buy | — | $108.62 | $96.53 | -11.1% | -15.1% | +0.1% | -2.4% | -2.5% | +6.0% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $108.62 | $96.53 | -11.1% | -15.1% | +0.1% | -2.4% | -2.5% | +6.0% |
| Jan 30 | Morgan Stanley | Maintains | Overweight → Overweight | — | $102.92 | $102.85 | -0.1% | +0.3% | +0.6% | +1.6% | -1.4% | -5.5% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $94.29 | $96.17 | +2.0% | +2.8% | +2.4% | +1.6% | +2.1% | +0.3% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $89.50 | $90.34 | +0.9% | +1.1% | +0.2% | +1.8% | -1.4% | +0.9% |
| Dec 19 | Citizens | Maintains | Market Outperform → Market Outperform | — | $70.28 | $71.06 | +1.1% | +10.6% | +4.3% | -1.3% | +0.9% | -1.8% |
| Dec 16 | Stifel | Maintains | Buy → Buy | — | $64.10 | $64.49 | +0.6% | +4.6% | +2.9% | +1.9% | +10.6% | +4.3% |
| Dec 9 | Baird | Maintains | Outperform → Outperform | — | $67.90 | $67.87 | -0.0% | -3.7% | -1.1% | +1.6% | -1.1% | -1.4% |
| Dec 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $67.90 | $67.87 | -0.0% | -3.7% | -1.1% | +1.6% | -1.1% | -1.4% |
| Dec 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $67.90 | $67.87 | -0.0% | -3.7% | -1.1% | +1.6% | -1.1% | -1.4% |
| Dec 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $68.48 | $68.74 | +0.4% | -0.8% | -3.7% | -1.1% | +1.6% | -1.1% |
| Nov 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $70.97 | $73.43 | +3.5% | -1.2% | -3.4% | +0.6% | +2.3% | +2.3% |
| Nov 5 | Citizens | Maintains | Market Outperform → Market Outperform | — | $70.97 | $73.43 | +3.5% | -1.2% | -3.4% | +0.6% | +2.3% | +2.3% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $70.97 | $73.43 | +3.5% | -1.2% | -3.4% | +0.6% | +2.3% | +2.3% |
| Oct 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $76.19 | $76.77 | +0.8% | -2.3% | -1.2% | -0.7% | -5.5% | +0.9% |
| Sep 12 | JP Morgan | Maintains | Overweight → Overweight | — | $75.99 | $76.11 | +0.2% | -2.2% | -0.2% | -0.5% | -0.9% | +3.0% |
| Aug 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $59.82 | $59.46 | -0.6% | +0.3% | +9.8% | -1.7% | +0.6% | -0.5% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $53.39 | $55.25 | +3.5% | +12.0% | +0.3% | +9.8% | -1.7% | +0.6% |
| Aug 7 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $53.39 | $55.25 | +3.5% | +12.0% | +0.3% | +9.8% | -1.7% | +0.6% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.39 | $55.25 | +3.5% | +12.0% | +0.3% | +9.8% | -1.7% | +0.6% |
| May 13 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $45.57 | $45.98 | +0.9% | -0.7% | -1.9% | +2.0% | -0.6% | -0.3% |
| May 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $45.24 | $45.27 | +0.1% | -2.1% | +2.9% | -0.7% | -1.9% | +2.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.98 | $46.35 | -1.3% | +1.3% | -3.3% | -1.7% | -1.3% | -2.7% |
| Feb 27 | Baird | Maintains | Outperform → Outperform | — | $50.52 | $49.00 | -3.0% | -7.0% | +1.3% | -3.3% | -1.7% | -1.3% |
| Feb 24 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $52.45 | $52.23 | -0.4% | -2.9% | -2.0% | +1.2% | -7.0% | +1.3% |
| Nov 13 | Citigroup | Maintains | Buy → Buy | — | $42.28 | $43.15 | +2.1% | +3.9% | +5.3% | -3.8% | -6.9% | +1.6% |
| Nov 13 | Baird | Maintains | Outperform → Outperform | — | $42.28 | $43.15 | +2.1% | +3.9% | +5.3% | -3.8% | -6.9% | +1.6% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.28 | $43.15 | +2.1% | +3.9% | +5.3% | -3.8% | -6.9% | +1.6% |
| Oct 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $39.78 | $39.64 | -0.4% | -1.2% | +0.4% | -0.3% | +0.8% | -3.2% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.48 | $38.48 | +0.0% | +4.2% | -0.8% | -0.2% | +0.2% | -1.2% |
| Aug 8 | Baird | Maintains | Outperform → Outperform | — | $38.96 | $38.96 | +0.0% | +2.3% | +0.4% | +11.8% | -8.2% | +1.0% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $38.96 | $38.96 | +0.0% | +2.3% | +0.4% | +11.8% | -8.2% | +1.0% |
| Aug 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $38.96 | $38.96 | +0.0% | +2.3% | +0.4% | +11.8% | -8.2% | +1.0% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.37 | $41.00 | +1.6% | +7.3% | -3.0% | -4.2% | +0.6% | -1.0% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.43 | $34.65 | +0.6% | +4.3% | +1.9% | -1.9% | +4.8% | +4.7% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.11 | $33.11 | +0.0% | +3.3% | -0.1% | -1.4% | +0.6% | +1.6% |
| Jun 20 | Stifel | Maintains | Buy → Buy | — | $29.25 | $30.00 | +2.6% | +6.5% | +2.9% | +8.7% | -4.9% | -0.8% |
| Jun 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $33.00 | $33.53 | +1.6% | -11.4% | +6.5% | +2.9% | +8.7% | -4.9% |
| Jun 18 | Citigroup | Maintains | Buy → Buy | — | $33.00 | $33.53 | +1.6% | -11.4% | +6.5% | +2.9% | +8.7% | -4.9% |
| Jun 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.00 | $33.53 | +1.6% | -11.4% | +6.5% | +2.9% | +8.7% | -4.9% |
No insider trades available.
8-K · 2.02
!! High
Mirum Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Mirum Pharmaceuticals reported its earnings results, with the detailed financial performance and management commentary available in the attached press release exhibit.
May 6
8-K
Mirum Pharmaceuticals, Inc. -- 8-K Filing
Mirum Pharmaceuticals' volixibat demonstrated acceptable safety in clinical trials with gastrointestinal side effects and liver enzyme elevations consistent with its drug class mechanism.
May 4
8-K · 2.02
!! High
Travere Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Travere Therapeutics reported earnings results, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 4
8-K
Mirum Pharmaceuticals, Inc. -- 8-K Filing
Mirum Pharmaceuticals will present Phase 2b AZURE-1 study results at EASL Congress in May 2026, providing investors key safety and efficacy data for its liver disease candidate.
Apr 27
8-K
Unknown — 8-K Filing
Mirum Pharmaceuticals completed a PIPE investment at $68.48/share with pre-funded warrants, providing capital for growth but diluting existing shareholders through new share issuance.
Apr 8
8-K
Mirum Pharmaceuticals, Inc. -- 8-K Filing
Mirum Pharmaceuticals reported $521 million in 2025 net product sales with guidance of $630-650 million for 2026, while advancing multiple clinical programs including volixibat, LIVMARLI, and brelovitug across PSC, cholestasis, and HDV indications.
Feb 25
Data updated apr 26, 2026 12:21pm
· Source: massive.com